# Gossamer Bio submits NDA for seralutinib for pulmonary arterial hypertension — retained record

> Retained news record from news:seeking-alpha.

Canonical: https://highsignal.app/data/records/e7c314b61b9dda5b

[← sources](https://highsignal.app/data)


source: [news](https://highsignal.app/data/news) (news:seeking-alpha)  published 2026-09-23 22:16 ingested 2026-09-24 02:52

[original source ↗](https://seekingalpha.com/news/4646399-gossamer-bio-submits-nda-seralutinib-pulmonary-arterial-hypertension?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news)

## retained text



```
Search fieldHome page Seeking Alpha - Power to InvestorsSearch for Symbols, analysts, keywordsAbout PremiumCreate free accountLog in

Gossamer Bio submits NDA for seralutinib for pulmonary arterial hypertension

Sep 23, 2026, 6:16 PM ETGossamer Bio, Inc. (GOSS) StockBy : Jonathan Block, SA News Editor

Gossamer Bio (GOSS) has submitted an NDA to the US FDA seeking approval of seralutinib for pulmonary arterial hypertension (PAH).

The application is supported by data from the phase 3 PROSERA study, evidence from the phase 2 TORREY study, and supportive analyses.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Search fieldEntering text into the input field will update the search result below

Recommended For You
```



document fetched 2026-09-24 02:52 · canonical https://seekingalpha.com/news/4646399-gossamer-bio-submits-nda-seralutinib-pulmonary-arterial-hypertension?feed_item_type=news